摘要:
A novel compound having an intense insecticidal activity and a process for producing the same which comprises culturing a strain belonging to the genus Humicola and isolating the compound from the culture.
摘要:
A new antibiotic SF-1771 substance is produced by cultivating a new strain, Streptomyces toyocaensis SF-1771, in a liquid culture medium under aerobic conditions. This antibiotic may be isolated from the fermentation broth by treating the broth filtrate with a synthetic adsorbent resin for adsorption of the active compound and eluting the resin with an aqueous alcohol or aqueous acetone, followed by chromatographic purification. SF-1771 substance is a copper-containing antibiotic which shows antibacterial activity against Escherichia coli, Salmonella typhi, Pseudomonas aeruginosa, Staphylococcus aureus and Bacillus subtilis. Removal of the copper component from SF-1771 substance by treatment with hydrogen sulfide, an alkali metal sulfide or a copper-chelating agent gives SF-1771-B substance containing no copper component which shows antibacterial activity as high as but a toxicity lower than SF-1771 substance.
摘要:
Novel antibiotics derivatives 7-(5-acylamido-5-carboxyvaleramido)-3-(.alpha.-methoxy-p-acyloxycinnamoyloxymethyl)-7-methoxy-3-cephem-4-carboxylic acids and the salts thereof which are useful as antibiotics and intermediates for the preparation of cephamycin derivatives, a process for preparing the same, and a process for recovering the cephamycin derivatives effectively and stably from the fermentation broth in the form of an N-acyl derivative.
摘要:
A new antibiotic designated as SF-1623 substance exhibiting a useful antibacterial activity against gram-negative bacteria is now produced by cultivating a new strain ATCC 21999 of the known species Streptomyces chartreusis. The SF-1623 substance in the form of its an alkali metal salt may be recovered from the culture when the cultivation is effected under aerobic conditions in the presence of an alkali metal thiosulfate.
摘要:
A BN-109 substance producing strain of the genus Bacillus is cultivated under an aerobic condition to produce and accumulate BN-109 substance in a culture medium. The BN-109 substance is isolated from the culture broth and purified, and proved to be a novel antibiotic. The BN-109 is effective in the treatment and prevention of swine scours.
摘要:
2,3-disubstituted-4-hydroxyquinoline derivatives of the general formula (I): ##STR1## [wherein R.sup.1 represents a hydrogen atom or R.sup.3 CO-- (wherein R.sup.3 is a lower alkyl group); R.sup.2 represents a hydrogen atom, --CH.sub.3 or --C.sub.2 H.sub.5 ; A represents ##STR2## and W represents a hydrogen atom, or 1- 4 halogen atoms or alkyl groups which are substituted at the nucleus and may be the same or different] have a strong antagonistic action on leukotriene D.sub.4.
摘要翻译:(I)的2,3-二取代-4-羟基喹啉衍生物:其中R1表示氢原子或R3CO-(其中R3是低级烷基); R 2表示氢原子,-CH 3或-C 2 H 5; A表示,W表示氢原子或1-4个卤原子或在核上被取代且可相同或不同的烷基对白三烯D4具有强拮抗作用。
摘要:
Essentially pure plasmids derived from Actinomycetes are described which have at least one restriction cleavage site for specific restriction enzyme and have molecular weight of less than 1.0.times.10.sup.7.
摘要:
Disclosed is a novel antibiotic SF-2107 series substance consisting essentially of Substance SF-2107 A-1, Substance SF-2107 B and/or Substance SF-2107 C, each having the phisico-chemical properties as described in the specification, which substance exhibits an antibacterial activity against both gram-positive and gram-negative bacteria and is useful for pharmaceuticals, bactericides, disinfectants, etc. Also disclosed is a process for preparing the substance.
摘要:
New antibiotics, SF-2050 substance and SF-2050B substance are produced by cultivating a microorganism Streptomyces sp. SF-2050 now deposited under FERM-P 4358 and under ATCC. 31450 in a liquid culture medium under aerobic conditions, and these antibiotics may be isolated from the fermentation broth and useful as an antibacterial agent. These antibiotics have an activity inhibitory to .beta.-lactamase.
摘要:
Disclosed is an antiviral agent comprising as an active component a substance SF-2140 described in detail in the specification, and a pharmaceutically acceptable carrier. Also disclosed is a method for treatment of viral diseases comprising administering a pharmaceutically effective amount of the substance SF-2140.